Alembic Pharmaceuticals Limited has received tentative approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Darolutamide Tablets, 300 mg — a generic equivalent to Bayer HealthCare Pharmaceuticals’ branded product Nubeqa Tablets, 300 mg. The approval was announced on May 14, 2026, through a filing with BSE and NSE.
What is Darolutamide and why does it matter?
Darolutamide is an androgen receptor inhibitor used in the treatment of adult patients with prostate cancer across three indications — non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and metastatic castration-sensitive prostate cancer in combination with docetaxel chemotherapy. It is a significant oncology product in the branded market, sold by Bayer under the trade name Nubeqa.
According to IQVIA data, Darolutamide Tablets 300 mg have an estimated market size of USD 3,155 million for the twelve months ending March 2026 — making this one of the larger addressable markets in Alembic’s US generics pipeline. The market size of over $3 billion underscores the commercial significance of the tentative approval, even though a tentative approval does not allow immediate commercial launch.
What does a tentative approval mean?
A USFDA tentative approval indicates that the ANDA has met all scientific, safety, and manufacturing requirements for approval, but the generic cannot be commercially launched in the US market until certain additional conditions are met. These typically include the expiry of existing patent protections or exclusivity periods held by the reference listed drug’s innovator — in this case Bayer’s Nubeqa. Once those exclusivities expire or are resolved through patent litigation, Alembic would be positioned to launch the generic version and compete for a share of the $3.15 billion market.
Alembic’s ANDA track record
The Darolutamide tentative approval takes Alembic Pharmaceuticals’ cumulative ANDA approvals from USFDA to 238 — comprising 219 final approvals and 19 tentative approvals. The company, headquartered in Vadodara and founded in 1907, is a vertically integrated pharmaceutical manufacturer with research and manufacturing facilities approved by regulatory authorities across multiple developed markets including the USFDA. Its branded generics business in India is supported by a field force of over 5,500 medical representatives.
The Darolutamide approval adds another significant oncology asset to Alembic’s US generics portfolio at a time when the company’s India-listed stock — trading on NSE as APLLTD and on BSE under scrip code 533573 — is navigating the broader sector environment that has been shaped this week by Cipla’s Q4 margin collapse and the Indian pharmaceutical sector’s ongoing cost pressures from freight and API procurement.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult a registered financial advisor before making any investment decisions. Business Upturn does not hold any position in the securities mentioned.